Celldex Therapeutics Inc (CLDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has a cash flow conversion efficiency ratio of -0.144x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.59 Million) by net assets ($456.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celldex Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1986–2025)
This chart illustrates how Celldex Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Celldex Therapeutics Inc (CLDX) total liabilities for a breakdown of total debt and financial obligations.
Celldex Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celldex Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Optics Technology Holding Co Ltd
SHE:300489
|
-0.004x |
|
Astronics Corporation
NASDAQ:ATRO
|
0.197x |
|
Alpha Metallurgical Resources Inc
NYSE:AMR
|
0.032x |
|
Minerals Technologies Inc
NYSE:MTX
|
0.018x |
|
Bomin Electronics Co Ltd
SHG:603936
|
0.009x |
|
Sopra Steria Group SA
PA:SOP
|
-0.025x |
|
By health
SHE:300146
|
0.025x |
|
TransMedics Group Inc
NASDAQ:TMDX
|
0.073x |
Annual Cash Flow Conversion Efficiency for Celldex Therapeutics Inc (1986–2025)
The table below shows the annual cash flow conversion efficiency of Celldex Therapeutics Inc from 1986 to 2025. For the full company profile with market capitalisation and key ratios, see CLDX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $527.16 Million | $-210.94 Million | -0.400x | -89.45% |
| 2024-12-31 | $747.00 Million | $-157.78 Million | -0.211x | +15.51% |
| 2023-12-31 | $429.17 Million | $-107.29 Million | -0.250x | +21.38% |
| 2022-12-31 | $326.20 Million | $-103.73 Million | -0.318x | -119.00% |
| 2021-12-31 | $419.48 Million | $-60.91 Million | -0.145x | +24.76% |
| 2020-12-31 | $209.36 Million | $-40.40 Million | -0.193x | +60.90% |
| 2019-12-31 | $94.03 Million | $-46.41 Million | -0.494x | +18.60% |
| 2018-12-31 | $124.06 Million | $-75.23 Million | -0.606x | -43.44% |
| 2017-12-31 | $236.37 Million | $-99.93 Million | -0.423x | +0.72% |
| 2016-12-31 | $265.43 Million | $-113.04 Million | -0.426x | -24.93% |
| 2015-12-31 | $290.11 Million | $-98.89 Million | -0.341x | +28.94% |
| 2014-12-31 | $211.66 Million | $-101.54 Million | -0.480x | -126.71% |
| 2013-12-31 | $319.80 Million | $-67.67 Million | -0.212x | +59.29% |
| 2012-12-31 | $95.77 Million | $-49.78 Million | -0.520x | -0.18% |
| 2011-12-31 | $68.72 Million | $-35.66 Million | -0.519x | -28.57% |
| 2010-12-31 | $75.25 Million | $-30.37 Million | -0.404x | +0.33% |
| 2009-12-31 | $73.77 Million | $-29.87 Million | -0.405x | -140.17% |
| 2008-12-31 | $18.13 Million | $18.28 Million | 1.008x | -0.54% |
| 2007-12-31 | $-19.04 Million | $-19.30 Million | 1.014x | -91.89% |
| 2006-12-31 | $2.16 Million | $27.00 Million | 12.494x | +4437.96% |
| 2005-12-31 | $20.89 Million | $-6.02 Million | -0.288x | -6.91% |
| 2004-12-31 | $38.41 Million | $-10.35 Million | -0.269x | +35.92% |
| 2003-12-31 | $27.92 Million | $-11.74 Million | -0.420x | +20.89% |
| 2002-12-31 | $31.34 Million | $-16.66 Million | -0.531x | -15.53% |
| 2001-12-31 | $45.27 Million | $-20.83 Million | -0.460x | -459.83% |
| 2000-12-31 | $53.93 Million | $-4.43 Million | -0.082x | +83.24% |
| 1999-12-31 | $17.41 Million | $-8.54 Million | -0.490x | -3.59% |
| 1998-12-31 | $18.80 Million | $-8.90 Million | -0.473x | +61.27% |
| 1997-12-31 | $6.30 Million | $-7.70 Million | -1.222x | -96.56% |
| 1996-12-31 | $15.60 Million | $-9.70 Million | -0.622x | -25.93% |
| 1995-12-31 | $16.00 Million | $-7.90 Million | -0.494x | +4.51% |
| 1994-12-31 | $17.60 Million | $-9.10 Million | -0.517x | -173.56% |
| 1993-12-31 | $29.10 Million | $-5.50 Million | -0.189x | +3.08% |
| 1992-12-31 | $20.00 Million | $-3.90 Million | -0.195x | +32.40% |
| 1991-12-31 | $10.40 Million | $-3.00 Million | -0.288x | 0.00% |
| 1990-12-31 | $10.40 Million | $-3.00 Million | -0.288x | -439.84% |
| 1989-12-31 | $13.10 Million | $-700.00K | -0.053x | +35.88% |
| 1988-12-31 | $8.40 Million | $-700.00K | -0.083x | -107.05% |
| 1986-12-31 | $10.40 Million | $12.30 Million | 1.183x | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more